Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.11B | 1.89B | 1.46B | 1.14B | 925.92M |
Gross Profit | 656.30M | 524.50M | 432.44M | 328.15M | 278.73M |
EBITDA | 476.12M | 363.15M | 301.04M | 219.73M | 186.57M |
Net Income | 404.39M | 282.81M | 245.37M | 181.85M | 145.38M |
Balance Sheet | |||||
Total Assets | 2.10B | 1.66B | 1.35B | 1.66B | 1.39B |
Cash, Cash Equivalents and Short-Term Investments | 669.44M | 245.45M | 28.27M | 461.30M | 277.77M |
Total Debt | 149.52M | 142.12M | 188.87M | 130.97M | 115.14M |
Total Liabilities | 1.28B | 1.10B | 966.11M | 707.01M | 584.90M |
Stockholders Equity | 825.54M | 558.95M | 386.39M | 952.93M | 805.78M |
Cash Flow | |||||
Free Cash Flow | 572.27M | 396.73M | 351.17M | 235.06M | 227.34M |
Operating Cash Flow | 608.82M | 433.37M | 388.05M | 263.33M | 258.68M |
Investing Cash Flow | -28.31M | -34.63M | -38.74M | -31.36M | -31.21M |
Financing Cash Flow | -154.01M | -182.64M | -775.77M | -44.45M | -82.28M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $43.48B | 49.96 | 59.33% | ― | 5.56% | 4.66% | |
78 Outperform | $12.29B | 32.53 | 89.38% | ― | 9.94% | 25.30% | |
70 Outperform | $8.25B | 449.94 | -0.92% | ― | -2.16% | -107.31% | |
67 Neutral | $12.02B | 39.32 | 3.82% | 0.27% | 1.62% | 78.53% | |
62 Neutral | $13.56B | 17.26 | 8.30% | ― | -2.91% | 12.92% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% |
On July 17, 2025, Medpace Holdings, Inc. announced an amendment to its unsecured credit facility with PNC Bank, increasing the line of credit to $10 million. For the second quarter of 2025, Medpace reported a 14.2% increase in revenue to $603.3 million and a 16.2% rise in EBITDA to $130.5 million compared to the previous year. The company also repurchased shares worth $518.5 million during the quarter. Despite a slight decrease in backlog, Medpace’s financial results reflect strong growth and operational efficiency, positioning it well within the industry.
The most recent analyst rating on (MEDP) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.
On May 16, 2025, Medpace Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were approved. The stockholders approved the 2016 Amended and Restated Incentive Award Plan, which extended the expiration date to February 6, 2035, without increasing the number of shares for issuance. Additionally, the election of Class III Directors, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and the advisory vote on executive compensation were all approved. A non-binding advisory stockholder proposal regarding simple majority voting was also passed.
The most recent analyst rating on (MEDP) stock is a Hold with a $345.00 price target. To see the full list of analyst forecasts on Medpace Holdings stock, see the MEDP Stock Forecast page.